MA43310A - Protéines de fusion de fmdv et e2 et leurs utilisations - Google Patents

Protéines de fusion de fmdv et e2 et leurs utilisations

Info

Publication number: MA43310A
Authority: MA; Morocco
Prior art keywords: fmdv; fusion proteins; fusion; proteins
Prior art date: 2015-11-23

Application number

MA043310A

Other languages

English (en)

Inventor

Jean-Christophe Audonnet

Natalia Bomchil

Frederic Reynard

Cecile Sigoillot-Claude

Original Assignee

Boehringer Ingelheim Animal Health Usa Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-11-23

Filing date

2016-11-16

Publication date

2021-04-28

2016-11-16 Application filed by Boehringer Ingelheim Animal Health Usa Inc filed Critical Boehringer Ingelheim Animal Health Usa Inc

2021-04-28 Publication of MA43310A publication Critical patent/MA43310A/fr

Links

241000710198 Foot-and-mouth disease virus Species 0.000 title 1
102000037865 fusion proteins Human genes 0.000 title 1
108020001507 fusion proteins Proteins 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/135—Foot- and mouth-disease virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32171—Demonstrated in vivo effect

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

MA043310A 2015-11-23 2016-11-16 Protéines de fusion de fmdv et e2 et leurs utilisations MA43310A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201562259043P	2015-11-23	2015-11-23

Publications (1)

Publication Number	Publication Date
MA43310A true MA43310A (fr)	2021-04-28

Family

ID=57570585

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
MA043310A MA43310A (fr)	2015-11-23	2016-11-16	Protéines de fusion de fmdv et e2 et leurs utilisations
MA049414A MA49414A (fr)	2015-11-23	2016-11-16	Protéines de fusion de dmdv et e2 et leurs utilisations
MA42640A MA42640B1 (fr)	2015-11-23	2016-11-16	Protéines de fusion de dmdv et e2 et leurs utilisations

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
MA049414A MA49414A (fr)	2015-11-23	2016-11-16	Protéines de fusion de dmdv et e2 et leurs utilisations
MA42640A MA42640B1 (fr)	2015-11-23	2016-11-16	Protéines de fusion de dmdv et e2 et leurs utilisations

Country Status (19)

Country	Link
US (2)	US9913891B2 (fr)
EP (2)	EP3539566A1 (fr)
JP (2)	JP6797206B2 (fr)
KR (1)	KR102153303B1 (fr)
CN (1)	CN108367067B (fr)
AR (1)	AR106792A1 (fr)
AU (1)	AU2016361305B2 (fr)
BR (1)	BR112018010494A8 (fr)
CA (1)	CA3006078A1 (fr)
DK (1)	DK3380119T3 (fr)
ES (1)	ES2899230T3 (fr)
MA (3)	MA43310A (fr)
MX (1)	MX382535B (fr)
NZ (1)	NZ743236A (fr)
RU (1)	RU2714428C2 (fr)
TW (1)	TWI744260B (fr)
UY (1)	UY36995A (fr)
WO (1)	WO2017091418A1 (fr)
ZA (1)	ZA201803390B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3824906A1 (fr)	2016-12-21	2021-05-26	Amgen Inc.	Formulations d'anticorps anti-tnf alpha
MX2020009720A (es) *	2018-03-19	2021-01-08	Boehringer Ingelheim Vetmedica China Co Ltd	Virus recombinante capaz de expresar de manera estable proteinas objetivo.
CN109187993B (zh) *	2018-09-13	2020-06-16	中国农业科学院兰州兽医研究所	一种口蹄疫A型病毒sIgA抗体ELISA检测试剂盒及其应用
CN111233984B (zh) *	2018-11-29	2022-08-12	普莱柯生物工程股份有限公司	一种o型口蹄疫病毒样颗粒抗原、及其疫苗组合物、制备方法和应用
CN110028160B (zh) *	2019-01-24	2022-04-29	暨南大学	一种功能性微藻固定化材料的制备方法及其应用
WO2020263062A1 (fr) *	2019-06-28	2020-12-30	(주)플럼라인생명과학	Composition vaccinale contre le virus de la fièvre aphteuse
CN115925907B (zh) *	2022-09-19	2025-08-05	北京田园奥瑞生物科技有限公司	一种羊口蹄疫纳米抗体及其在精液保藏检测中的应用
CN119505021B (zh) *	2025-01-20	2025-04-18	内蒙古和讯生物科技有限公司	一种重复结构单元重组蛋白cpE2及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2909462A (en)	1955-12-08	1959-10-20	Bristol Myers Co	Acrylic acid polymer laxative compositions
US5505941A (en)	1981-12-24	1996-04-09	Health Research, Inc.	Recombinant avipox virus and method to induce an immune response
CA1247080A (fr)	1983-03-08	1988-12-20	Commonwealth Serum Laboratories Commission	Sequences d'acides amines ayant une activite antigenique
EP0173552B1 (fr)	1984-08-24	1991-10-09	The Upjohn Company	Composés recombinants d'ADN et l'expression de polypeptides comme le tPA
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4963481A (en)	1985-12-18	1990-10-16	Genetics Institute Inc	Promoter system
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
GB2197321B (en)	1986-09-12	1990-10-03	Genentech Inc	Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
DE3743138A1 (de)	1987-12-18	1989-09-14	Mayr Christian Gmbh & Co Kg	Schleifringlose, elektromagnetische ueberlastkupplung
EP0575491B1 (fr)	1991-03-07	2003-08-13	Virogenetics Corporation	Souche de vaccin mise au point par genie genetique
JPH11504631A (ja)	1995-04-25	1999-04-27	バイカルインコーポレイテッド	Ｄｎａ／脂質複合体の単一バイアル製剤
US5846946A (en)	1996-06-14	1998-12-08	Pasteur Merieux Serums Et Vaccins	Compositions and methods for administering Borrelia DNA
FR2751225B1 (fr)	1996-07-19	1998-11-27	Rhone Merieux	Formule de vaccin polynucleotidique aviaire
FR2751224B1 (fr)	1996-07-19	1998-11-20	Rhone Merieux	Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751228B1 (fr)	1996-07-19	1998-11-20	Rhone Merieux	Vaccin polynucleotidique bovin pour voie intradermique
FR2751227B1 (fr)	1996-07-19	1998-11-27	Rhone Merieux	Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751229B1 (fr)	1996-07-19	1998-11-27	Rhone Merieux	Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751226B1 (fr)	1996-07-19	1998-11-27	Rhone Merieux	Formule de vaccin polynucleotidique contre les pathologies du cheval
WO1998016247A1 (fr)	1996-10-11	1998-04-23	The Regents Of The University Of California	Conjugues polynucleotide immunostimulateur/molecule immunomodulatrice
CA2294793A1 (fr)	1997-06-30	1999-01-14	Rhone-Poulenc Rorer S.A.	Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
FR2778858B1 (fr)	1998-05-20	2000-06-16	Oreal	Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
FR2801607B1 (fr)	1999-11-26	2001-12-28	Merial Sas	Pneumovirus du canard et vaccins correspondants
GB9929151D0 (en) *	1999-12-09	2000-02-02	Univ Cambridge Tech	Peptide and polypeptide display
US6852705B2 (en)	2000-01-21	2005-02-08	Merial	DNA vaccines for farm animals, in particular bovines and porcines
PL1651265T3 (pl)	2003-07-24	2008-10-31	Merial Ltd	Formulacje szczepionek zawierających emulsję olej w wodzie
US7527960B2 (en)	2004-06-25	2009-05-05	Merial Limited	Avipox recombinants expressing foot and mouth disease virus genes
US7691368B2 (en)	2005-04-15	2010-04-06	Merial Limited	Vaccine formulations
US20070160628A1 (en) *	2005-08-31	2007-07-12	Birkett Ashley J	Stabilized virus-like particles and epitope display systems
DK1994156T3 (da) *	2006-03-17	2011-10-31	Indian Immunologicals Ltd	Kimæriske tymoviruslignende partikler
CN101293098A (zh) *	2007-04-28	2008-10-29	北京迪威华宇生物技术有限公司	一种重组牛o型口蹄疫病毒融合蛋白疫苗
DK2475384T3 (en)	2009-09-10	2016-10-24	Merial Inc	NEW VACCINE FORMULATIONS COMPREHENSIVE saponin-CONTAINING ADJUVANTS
WO2011112945A2 (fr) *	2010-03-12	2011-09-15	Merial Limited	Vaccins de recombinaison contre le virus de la fièvre aphteuse et utilisations de ceux-ci
RU2467014C2 (ru) *	2010-12-06	2012-11-20	Учреждение Российской академии наук Центр "Боинженерия" РАН	Полиэпитопный белок, нуклеотидная последовательность, кодирующая полиэпитопный белок, плазмида с последовательностью, кодирующей полиэпитопный белок, и препарат полиэпитопного белка для индукции иммунного ответа против вируса ящура
KR20150084993A (ko) *	2012-11-16	2015-07-22	유나이티드 바이오메디칼 인크.	구제역 (fmd)에 대한 합성 펩티드-기재 응급 백신
CN109608550B (zh) *	2012-12-05	2020-09-11	生控基因疫苗股份有限公司	用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
CN103305542B (zh) *	2013-06-25	2015-03-11	江苏省农业科学院	一种重组噬菌体双表达载体及应用
EP3054971B1 (fr) *	2013-10-11	2021-03-10	The United States of America, represented by the Secretary, Department of Health and Human Services	Vaccins contre le virus d'epstein-barr
CN103933581A (zh) *	2014-05-04	2014-07-23	贵州大学	一种基于csf-fmd二联基因工程疫苗的制备方法
US10010605B2 (en)	2014-09-23	2018-07-03	Merial, Inc.	FMDV recombinant vaccines and uses thereof

2016
- 2016-11-16 JP JP2018545561A patent/JP6797206B2/ja not_active Expired - Fee Related
- 2016-11-16 CA CA3006078A patent/CA3006078A1/fr active Pending
- 2016-11-16 AU AU2016361305A patent/AU2016361305B2/en not_active Ceased
- 2016-11-16 BR BR112018010494A patent/BR112018010494A8/pt not_active IP Right Cessation
- 2016-11-16 CN CN201680075080.4A patent/CN108367067B/zh active Active
- 2016-11-16 ES ES16813258T patent/ES2899230T3/es active Active
- 2016-11-16 MA MA043310A patent/MA43310A/fr unknown
- 2016-11-16 US US15/353,727 patent/US9913891B2/en active Active
- 2016-11-16 MA MA049414A patent/MA49414A/fr unknown
- 2016-11-16 RU RU2018122755A patent/RU2714428C2/ru active
- 2016-11-16 MA MA42640A patent/MA42640B1/fr unknown
- 2016-11-16 EP EP19167578.4A patent/EP3539566A1/fr active Pending
- 2016-11-16 KR KR1020187017812A patent/KR102153303B1/ko not_active Expired - Fee Related
- 2016-11-16 MX MX2018006347A patent/MX382535B/es unknown
- 2016-11-16 NZ NZ743236A patent/NZ743236A/en not_active IP Right Cessation
- 2016-11-16 WO PCT/US2016/062367 patent/WO2017091418A1/fr not_active Ceased
- 2016-11-16 DK DK16813258.7T patent/DK3380119T3/da active
- 2016-11-16 EP EP16813258.7A patent/EP3380119B1/fr active Active
- 2016-11-23 UY UY0001036995A patent/UY36995A/es not_active Application Discontinuation
- 2016-11-23 TW TW105138385A patent/TWI744260B/zh not_active IP Right Cessation
- 2016-11-23 AR ARP160103584A patent/AR106792A1/es unknown
2018
- 2018-02-05 US US15/888,718 patent/US10363300B2/en active Active
- 2018-05-22 ZA ZA2018/03390A patent/ZA201803390B/en unknown
2020
- 2020-08-06 JP JP2020133788A patent/JP2020203890A/ja active Pending

Also Published As

Publication number	Publication date
US20170143819A1 (en)	2017-05-25
MX382535B (es)	2025-03-13
JP2020203890A (ja)	2020-12-24
MA42640A1 (fr)	2019-05-31
AU2016361305B2 (en)	2020-02-06
CN108367067A (zh)	2018-08-03
MA42640B1 (fr)	2021-06-30
JP2019500409A (ja)	2019-01-10
HK1258695A1 (en)	2019-11-15
EP3380119A1 (fr)	2018-10-03
US9913891B2 (en)	2018-03-13
ES2899230T3 (es)	2022-03-10
WO2017091418A1 (fr)	2017-06-01
KR20180084995A (ko)	2018-07-25
DK3380119T3 (da)	2021-11-15
AU2016361305A1 (en)	2018-06-28
EP3380119B1 (fr)	2021-08-25
RU2018122755A3 (fr)	2019-12-26
TWI744260B (zh)	2021-11-01
BR112018010494A2 (pt)	2018-11-13
US10363300B2 (en)	2019-07-30
CA3006078A1 (fr)	2017-06-01
MA49414A (fr)	2020-04-22
AR106792A1 (es)	2018-02-21
EP3539566A1 (fr)	2019-09-18
BR112018010494A8 (pt)	2019-02-26
UY36995A (es)	2017-06-30
RU2018122755A (ru)	2019-12-26
MX2018006347A (es)	2019-02-20
NZ743236A (en)	2019-12-20
TW201726708A (zh)	2017-08-01
CN108367067B (zh)	2022-05-03
US20180169216A1 (en)	2018-06-21
JP6797206B2 (ja)	2020-12-09
RU2714428C2 (ru)	2020-02-14
KR102153303B1 (ko)	2020-09-09
ZA201803390B (en)	2019-03-27

Publication	Publication Date	Title
FR24C1052I2 (fr)	2026-04-03	Protéines chimériques de facteur viii et leurs utilisations
FR24C1023I2 (fr)	2026-04-03	Anticorps thérapeutiques et leurs utilisations
MA44986A (fr)	2019-03-20	Protéines de fusion gdf15 et leurs utilisations
MA44885A (fr)	2019-03-13	Protéines de liaison bispécifiques et leurs utilisations
IL254165B (en)	2021-08-31	Immunomodulatory fusion proteins and uses thereof
MA49537A (fr)	2020-05-13	Anticorps anti-lag3 et leurs utilisations
MA50618A (fr)	2020-08-12	Polyrhérapies et leurs utilisations
EP3352776A4 (fr)	2019-03-13	Répresseurs htt et leurs utilisations
MA46471A (fr)	2021-05-19	Protéines actriib à variant et leurs utilisations
EP3334706A4 (fr)	2019-03-13	Pillararènes et utilisations de ceux-ci
DK3292141T3 (da)	2020-04-20	Fusionsproteiner
MA46704A (fr)	2019-09-11	Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3283516A4 (fr)	2019-03-06	Anticorps anti-pacap et leurs utilisations
EP3328895A4 (fr)	2019-08-21	Anticorps anti-pd-l1 et leurs utilisations
EP3383904A4 (fr)	2019-12-04	Anticorps ctla-4 et leurs utilisations
EP3325010A4 (fr)	2019-03-27	Anticorps anti-facteur de coagulation xia et leurs utilisations
MA43567A (fr)	2018-11-14	Anticorps pacap et leurs utilisations
MA45125A (fr)	2021-06-02	Anticorps anti-alpha-synucléine et leurs utilisations
MA49414A (fr)	2020-04-22	Protéines de fusion de dmdv et e2 et leurs utilisations
EP3344278A4 (fr)	2019-01-23	Protéines de fusion immunoglobuline-insuline
EP3894548A4 (fr)	2022-08-31	Polypeptides de cétoréductase modifiés et leurs utilisations
EP3347021A4 (fr)	2019-07-24	Cyano-thiénotriazoloazépines et leurs utilisations
EP3668551A4 (fr)	2021-04-14	Protéines de fusion apom-fc et leurs utilisations
MA53991A (fr)	2021-09-15	Protéines de fusion de l'inhibiteur de la c1 estérase et leurs utilisations
EP3370771A4 (fr)	2019-06-19	Conjugués anti-cd3-folate et leurs utilisations